Trial Outcomes & Findings for QUILT-3.005: A Study of N-803 in Patients With Relapsed or Refractory Multiple Myeloma (NCT NCT02099539)
NCT ID: NCT02099539
Last Updated: 2024-09-26
Results Overview
For phase I - Number of Participants with Treatment Emergent Adverse Events that occur or worsen after the first dose of study treatment.
Recruitment status
TERMINATED
Study phase
PHASE1
Target enrollment
19 participants
Primary outcome timeframe
24 weeks
Results posted on
2024-09-26
Participant Flow
Only the Phase 1b portion of the study enrolled participants. The study was terminated early, so no participants were enrolled on the Phase 2 portion of the study
Participant milestones
| Measure |
Cohort 1: N-803 - IV 1 ug/kg
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 2: N-803 - IV 3 ug/kg
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 3: N-803 - IV 6 ug/kg
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 4: N-803 - IV 10 ug/kg
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 5: N-803 - SQ 10 ug/kg
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 6: N-803 - SQ 15 ug/kg
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 7: N-803 - SQ 20 ug/kg
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
|---|---|---|---|---|---|---|---|
|
Overall Study
STARTED
|
3
|
3
|
3
|
3
|
4
|
3
|
0
|
|
Overall Study
COMPLETED
|
0
|
1
|
0
|
1
|
0
|
0
|
0
|
|
Overall Study
NOT COMPLETED
|
3
|
2
|
3
|
2
|
4
|
3
|
0
|
Reasons for withdrawal
| Measure |
Cohort 1: N-803 - IV 1 ug/kg
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 2: N-803 - IV 3 ug/kg
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 3: N-803 - IV 6 ug/kg
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 4: N-803 - IV 10 ug/kg
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 5: N-803 - SQ 10 ug/kg
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 6: N-803 - SQ 15 ug/kg
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 7: N-803 - SQ 20 ug/kg
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
|---|---|---|---|---|---|---|---|
|
Overall Study
Progressive Disease
|
3
|
2
|
2
|
1
|
4
|
2
|
0
|
|
Overall Study
Adverse Event
|
0
|
0
|
1
|
1
|
0
|
0
|
0
|
|
Overall Study
Physician Decision
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
Baseline Characteristics
QUILT-3.005: A Study of N-803 in Patients With Relapsed or Refractory Multiple Myeloma
Baseline characteristics by cohort
| Measure |
Cohort 1: ALT-803 - IV 1 ug/kg
n=3 Participants
ALT-803: Intravenous infusion for cohort 1, 2, 3 and 4; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 2: ALT-803 - IV 3 ug/kg
n=3 Participants
ALT-803: Intravenous infusion for cohort 1, 2, 3 and 4; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 3: ALT-803 - IV 6 ug/kg
n=3 Participants
ALT-803: Intravenous infusion for cohort 1, 2, 3 and 4; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 4: ALT-803 - IV 10 ug/kg
n=3 Participants
ALT-803: Intravenous infusion for cohort 1, 2, 3 and 4; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 5: ALT-803 - SQ 10 ug/kg
n=4 Participants
ALT-803: subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 6: ALT-803 - SQ 15 ug/kg
n=3 Participants
ALT-803: subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 7: ALT-803 - SQ 20 ug/kg
ALT-803: subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Total
n=19 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|---|
|
Patients with Relapsed or Refractory Multiple Myeloma
|
3 Participants
n=5 Participants
|
3 Participants
n=7 Participants
|
3 Participants
n=5 Participants
|
3 Participants
n=4 Participants
|
4 Participants
n=21 Participants
|
3 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
19 Participants
n=24 Participants
|
|
Age, Continuous
|
71.7 years
STANDARD_DEVIATION 4.16 • n=5 Participants
|
59.3 years
STANDARD_DEVIATION 6.66 • n=7 Participants
|
63.7 years
STANDARD_DEVIATION 6.35 • n=5 Participants
|
61.7 years
STANDARD_DEVIATION 12.1 • n=4 Participants
|
49.8 years
STANDARD_DEVIATION 22.63 • n=21 Participants
|
67.0 years
STANDARD_DEVIATION 5.0 • n=8 Participants
|
—
|
61.5 years
STANDARD_DEVIATION 13.05 • n=24 Participants
|
|
Sex: Female, Male
Female
|
2 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
3 Participants
n=5 Participants
|
2 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
2 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
9 Participants
n=24 Participants
|
|
Sex: Female, Male
Male
|
1 Participants
n=5 Participants
|
3 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
4 Participants
n=21 Participants
|
1 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
10 Participants
n=24 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
1 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
2 Participants
n=24 Participants
|
|
Race (NIH/OMB)
White
|
3 Participants
n=5 Participants
|
3 Participants
n=7 Participants
|
2 Participants
n=5 Participants
|
3 Participants
n=4 Participants
|
3 Participants
n=21 Participants
|
3 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
17 Participants
n=24 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
PRIMARY outcome
Timeframe: 24 weeksPopulation: Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
For phase I - Number of Participants with Treatment Emergent Adverse Events that occur or worsen after the first dose of study treatment.
Outcome measures
| Measure |
Cohort 6: N-803 - SQ 15 ug/kg
n=3 Participants
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 4: N-803 - IV 10 ug/kg
n=3 Participants
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 5: N-803 - SQ 10 ug/kg
n=4 Participants
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 1: N-803 - IV 1 ug/kg
n=3 Participants
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 2: N-803 - IV 3 ug/kg
n=3 Participants
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 3: N-803 - IV 6 ug/kg
n=3 Participants
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
|---|---|---|---|---|---|---|
|
Number of Participants With Treatment Emergent Adverse Events
|
3 Participants
|
3 Participants
|
4 Participants
|
3 Participants
|
3 Participants
|
3 Participants
|
PRIMARY outcome
Timeframe: Starts at Week 11 - 12 and Week 23 - 24Population: Cohort 5: N-803 - SQ 10 ug/kg - one subject only received 2 doses of study drug. This subject is not evaluable for tumor response assessment. Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
CR- negative SIFE and UIFE, disappearance of any soft tissue plasmacytomas, and \< or = to 5% plasma cells in bone marrow VGPR - either + SIFE and UIFE and - SPEP and UPEP or reduction in serum M-protein \> or = to 90% and urine m-protein level \<100mg per 24h PR - if measurable serum an urine m-protein them reduction of serum m-protein by \>=50% and reduction in 24h urinary m protein by \>=90% or to \<200mg per 24h if unmeasurable serum and urine m-protein then \>= 50% decrease in the difference between involve and uninvolved FLC levels If unmeasurable serum and urine m-protein and serum FLC assay then \>= 50% reduction in plasma cells, provide baseline bone marrow plasma cell percentage was \>=30% In addition to the above listed criteria, if present at baseline, a \>=50% reduction in the size of soft tissue plasmacytomas is also required PD - defined via International Myeloma Working Group uniform response criteria: disease progression SD - not meeting criteria for CR, VGPR, PR or PD
Outcome measures
| Measure |
Cohort 6: N-803 - SQ 15 ug/kg
n=3 Participants
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 4: N-803 - IV 10 ug/kg
n=3 Participants
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 5: N-803 - SQ 10 ug/kg
n=3 Participants
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 1: N-803 - IV 1 ug/kg
n=3 Participants
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 2: N-803 - IV 3 ug/kg
n=3 Participants
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 3: N-803 - IV 6 ug/kg
n=3 Participants
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
|---|---|---|---|---|---|---|
|
Disease Response Rate of Treated Patients
Stable Disease
|
1 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
|
Disease Response Rate of Treated Patients
Progressive Disease
|
2 Participants
|
2 Participants
|
2 Participants
|
3 Participants
|
2 Participants
|
1 Participants
|
|
Disease Response Rate of Treated Patients
Not available to evaluate
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
SECONDARY outcome
Timeframe: PK timepoint up to 72 hours +/- 6 hoursPopulation: Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects. In addition, 6 out of 7 SC patients (Cohorts 5 and 6) had insufficient measurable post-tmax sampling to allow for evaluation of the terminal phase-dependent PK parameters (ie, t½, CL/F, Vz/F, AUC0-168, AUC0-∞).
Half-life (t½) - The period of time required for the concentration or amount of drug in the body to be reduced by one-half.
Outcome measures
| Measure |
Cohort 6: N-803 - SQ 15 ug/kg
n=1 Participants
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 4: N-803 - IV 10 ug/kg
n=3 Participants
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 5: N-803 - SQ 10 ug/kg
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 1: N-803 - IV 1 ug/kg
n=3 Participants
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 2: N-803 - IV 3 ug/kg
n=2 Participants
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 3: N-803 - IV 6 ug/kg
n=2 Participants
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
|---|---|---|---|---|---|---|
|
Characterization of the Pharmacokinetic Profile - Half-life (t½)
|
35.3 Hours
Interval 35.3 to 35.3
|
3.07 Hours
Interval 2.33 to 4.14
|
—
|
0.773 Hours
Interval 0.734 to 0.826
|
2.41 Hours
Interval 2.4 to 2.41
|
2.21 Hours
Interval 2.02 to 2.39
|
SECONDARY outcome
Timeframe: PK timepoint up to 72 hours +/- 6 hoursPopulation: Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
time of the observed maximum concentration (Tmax)
Outcome measures
| Measure |
Cohort 6: N-803 - SQ 15 ug/kg
n=3 Participants
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 4: N-803 - IV 10 ug/kg
n=3 Participants
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 5: N-803 - SQ 10 ug/kg
n=4 Participants
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 1: N-803 - IV 1 ug/kg
n=3 Participants
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 2: N-803 - IV 3 ug/kg
n=3 Participants
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 3: N-803 - IV 6 ug/kg
n=3 Participants
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
|---|---|---|---|---|---|---|
|
Characterization of the Pharmacokinetic Profile - Time of the Observed Maximum Concentration (Tmax)
|
6.0 Hours
Interval 2.0 to 20.3
|
0.667 Hours
Interval 0.667 to 2.33
|
33.1 Hours
Interval 4.22 to 65.9
|
0.583 Hours
Interval 0.5 to 0.683
|
0.583 Hours
Interval 0.5 to 0.633
|
0.65 Hours
Interval 0.633 to 0.717
|
SECONDARY outcome
Timeframe: PK timepoint up to 72 hours +/- 6 hoursPopulation: Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
maximum observed concentration (Cmax)
Outcome measures
| Measure |
Cohort 6: N-803 - SQ 15 ug/kg
n=3 Participants
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 4: N-803 - IV 10 ug/kg
n=3 Participants
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 5: N-803 - SQ 10 ug/kg
n=4 Participants
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 1: N-803 - IV 1 ug/kg
n=3 Participants
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 2: N-803 - IV 3 ug/kg
n=3 Participants
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 3: N-803 - IV 6 ug/kg
n=3 Participants
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
|---|---|---|---|---|---|---|
|
Characterization of the Pharmacokinetic Profile - Maximum Observed Concentration (Cmax)
|
1.69 ng/mL
Standard Deviation 1.41
|
144 ng/mL
Standard Deviation 70.7
|
0.383 ng/mL
Standard Deviation 0.111
|
8.45 ng/mL
Standard Deviation 1.78
|
42.7 ng/mL
Standard Deviation 1.76
|
142 ng/mL
Standard Deviation 26.6
|
SECONDARY outcome
Timeframe: Samples were collected and the AUC was determined at 24 hours and at time t (last measurable concentration). The AUC was calculated for 168 hours and time to infinity.Population: Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects In addition, 6 out of 7 SC patients (Cohorts 5 and 6) had insufficient measurable post-tmax sampling to allow for evaluation of the terminal phase-dependent PK parameters (ie, t½, CL/F, Vz/F, AUC0-168, AUC0-∞).
Area under the plasma concentration curve from time 0 through the last measurable concentration (AUC0-t). PK samples were obtained from the start of treatment until 72 hours. The AUC0-168 and AUC0-inf were calculated with noncompartmental pharmacokinetic analysis equations.
Outcome measures
| Measure |
Cohort 6: N-803 - SQ 15 ug/kg
n=3 Participants
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 4: N-803 - IV 10 ug/kg
n=3 Participants
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 5: N-803 - SQ 10 ug/kg
n=4 Participants
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 1: N-803 - IV 1 ug/kg
n=3 Participants
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 2: N-803 - IV 3 ug/kg
n=3 Participants
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 3: N-803 - IV 6 ug/kg
n=3 Participants
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
|---|---|---|---|---|---|---|
|
Characterization of the Pharmacokinetic Profile - Area Under the Plasma Concentration Curve
AUC0-t
|
60.4 hr x ng/mL
Interval 9.61 to 135.0
|
808 hr x ng/mL
Interval 577.0 to 1200.0
|
13.6 hr x ng/mL
Interval 6.0 to 21.2
|
10.5 hr x ng/mL
Interval 7.58 to 13.7
|
129 hr x ng/mL
Interval 105.0 to 166.0
|
634 hr x ng/mL
Interval 439.0 to 845.0
|
|
Characterization of the Pharmacokinetic Profile - Area Under the Plasma Concentration Curve
AUC0-24
|
31.1 hr x ng/mL
Interval 11.7 to 65.5
|
811 hr x ng/mL
Interval 577.0 to 1220.0
|
5.01 hr x ng/mL
Interval 2.91 to 6.69
|
10.6 hr x ng/mL
Interval 7.62 to 13.8
|
141 hr x ng/mL
Interval 116.0 to 166.0
|
731 hr x ng/mL
Interval 618.0 to 845.0
|
|
Characterization of the Pharmacokinetic Profile - Area Under the Plasma Concentration Curve
AUC0-168
|
31.4 hr x ng/mL
Interval 31.4 to 31.4
|
813 hr x ng/mL
Interval 578.0 to 1220.0
|
—
|
10.6 hr x ng/mL
Interval 7.62 to 13.8
|
141 hr x ng/mL
Interval 116.0 to 166.0
|
732 hr x ng/mL
Interval 618.0 to 846.0
|
|
Characterization of the Pharmacokinetic Profile - Area Under the Plasma Concentration Curve
AUC0-inf
|
32.5 hr x ng/mL
Interval 32.5 to 32.5
|
814 hr x ng/mL
Interval 578.0 to 1220.0
|
—
|
10.6 hr x ng/mL
Interval 7.61 to 13.7
|
141 hr x ng/mL
Interval 116.0 to 166.0
|
732 hr x ng/mL
Interval 618.0 to 846.0
|
SECONDARY outcome
Timeframe: PK timepoint up to 72 hours +/- 6 hoursPopulation: Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects Cohorts 1-4 - Clearance (CL)
Clearance (CL)
Outcome measures
| Measure |
Cohort 6: N-803 - SQ 15 ug/kg
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 4: N-803 - IV 10 ug/kg
n=3 Participants
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 5: N-803 - SQ 10 ug/kg
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 1: N-803 - IV 1 ug/kg
n=3 Participants
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 2: N-803 - IV 3 ug/kg
n=2 Participants
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 3: N-803 - IV 6 ug/kg
n=2 Participants
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
|---|---|---|---|---|---|---|
|
Characterization of the Pharmacokinetic Profile - Clearance (CL)
|
—
|
13.7 mL/hr/kg
Interval 8.2 to 17.3
|
—
|
99.9 mL/hr/kg
Interval 72.7 to 131.0
|
22.0 mL/hr/kg
Interval 18.1 to 25.9
|
8.4 mL/hr/kg
Interval 7.09 to 9.71
|
SECONDARY outcome
Timeframe: PK timepoint up to 72 hours +/- 6 hoursPopulation: Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
Vss Volume of distribution at steady state is a ratio of the total amount of drug in the body to the plasma concentration of the drugs such that Vd = amount of drug in body/plasma drug concentration
Outcome measures
| Measure |
Cohort 6: N-803 - SQ 15 ug/kg
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 4: N-803 - IV 10 ug/kg
n=3 Participants
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 5: N-803 - SQ 10 ug/kg
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 1: N-803 - IV 1 ug/kg
n=3 Participants
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 2: N-803 - IV 3 ug/kg
n=2 Participants
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 3: N-803 - IV 6 ug/kg
n=2 Participants
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
|---|---|---|---|---|---|---|
|
Characterization of the Pharmacokinetic Profile - Vss Volume of Distribution at Steady State
|
—
|
62.8 mL/kg
Interval 39.0 to 78.0
|
—
|
126 mL/kg
Interval 101.0 to 159.0
|
71.8 mL/kg
Interval 65.9 to 77.8
|
34.0 mL/kg
Interval 30.2 to 37.8
|
SECONDARY outcome
Timeframe: From Baseline up to Week 12Population: Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
Number of patients with a positive Anti-drug Antibody (ADA) result
Outcome measures
| Measure |
Cohort 6: N-803 - SQ 15 ug/kg
n=3 Participants
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 4: N-803 - IV 10 ug/kg
n=2 Participants
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 5: N-803 - SQ 10 ug/kg
n=3 Participants
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 1: N-803 - IV 1 ug/kg
n=2 Participants
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 2: N-803 - IV 3 ug/kg
n=3 Participants
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 3: N-803 - IV 6 ug/kg
n=1 Participants
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
|---|---|---|---|---|---|---|
|
Immunogenicity - Anti-drug Antibody (ADA)
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: PK timepoint up to 72 hours +/- 6 hoursPopulation: In addition, 6 out of 7 SC patients (Cohorts 5 and 6) had insufficient measurable post-tmax sampling to allow for evaluation of the terminal phase-dependent PK parameters (ie, t½, CL/F, Vz/F, AUC0-168, AUC0-∞).
Apparent (Extravascular) Clearance (CL/F)
Outcome measures
| Measure |
Cohort 6: N-803 - SQ 15 ug/kg
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 4: N-803 - IV 10 ug/kg
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 5: N-803 - SQ 10 ug/kg
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 1: N-803 - IV 1 ug/kg
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 2: N-803 - IV 3 ug/kg
n=1 Participants
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 3: N-803 - IV 6 ug/kg
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
|---|---|---|---|---|---|---|
|
Characterization of the Pharmacokinetic Profile - Apparent (Extravascular) Clearance (CL/F)
|
—
|
—
|
—
|
—
|
462 mL/hr/kg
Interval 462.0 to 462.0
|
—
|
SECONDARY outcome
Timeframe: PK timepoint up to 72 hours +/- 6 hoursPopulation: Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects In addition, 6 out of 7 SC patients (Cohorts 5 and 6) had insufficient measurable post-tmax sampling to allow for evaluation of the terminal phase-dependent PK parameters (ie, t½, CL/F, Vz/F, AUC0-168, AUC0-∞).
Apparent volume of distribution is a ratio of the total amount of drug in the body to the plasma concentration of the drugs such that Vd = amount of drug in body/plasma drug concentration
Outcome measures
| Measure |
Cohort 6: N-803 - SQ 15 ug/kg
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 4: N-803 - IV 10 ug/kg
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 5: N-803 - SQ 10 ug/kg
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 1: N-803 - IV 1 ug/kg
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 2: N-803 - IV 3 ug/kg
n=1 Participants
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 3: N-803 - IV 6 ug/kg
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
|---|---|---|---|---|---|---|
|
Characterization of the Pharmacokinetic Profile - Apparent (Extravascular) Volume of Distribution (Vz/F)
|
—
|
—
|
—
|
—
|
23500 mL/kg
Interval 23500.0 to 23500.0
|
—
|
Adverse Events
Cohort 1: N-803 - IV 1 ug/kg
Serious events: 2 serious events
Other events: 3 other events
Deaths: 2 deaths
Cohort 2: N-803 - IV 3 ug/kg
Serious events: 1 serious events
Other events: 3 other events
Deaths: 0 deaths
Cohort 3: N-803 - IV 6 ug/kg
Serious events: 1 serious events
Other events: 3 other events
Deaths: 1 deaths
Cohort 4: N-803 - IV 10 ug/kg
Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths
Cohort 5: N-803 - SQ 10 ug/kg
Serious events: 3 serious events
Other events: 4 other events
Deaths: 3 deaths
Cohort 6: N-803 - SQ 15 ug/kg
Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths
Cohort 7: N-803 - SQ 20 ug/kg
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
| Measure |
Cohort 1: N-803 - IV 1 ug/kg
n=3 participants at risk
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 2: N-803 - IV 3 ug/kg
n=3 participants at risk
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 3: N-803 - IV 6 ug/kg
n=3 participants at risk
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 4: N-803 - IV 10 ug/kg
n=3 participants at risk
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 5: N-803 - SQ 10 ug/kg
n=4 participants at risk
N-803: subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 6: N-803 - SQ 15 ug/kg
n=3 participants at risk
N-803: subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 7: N-803 - SQ 20 ug/kg
N-803: subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
|---|---|---|---|---|---|---|---|
|
Cardiac disorders
Cardiac arrest
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
25.0%
1/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
General disorders
Pyrexia
|
66.7%
2/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
25.0%
1/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Metabolism and nutrition disorders
Dehydration
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Metabolism and nutrition disorders
Hypercalcaemia
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
25.0%
1/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
75.0%
3/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
25.0%
1/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Nervous system disorders
Ataxia
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
Other adverse events
| Measure |
Cohort 1: N-803 - IV 1 ug/kg
n=3 participants at risk
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 2: N-803 - IV 3 ug/kg
n=3 participants at risk
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 3: N-803 - IV 6 ug/kg
n=3 participants at risk
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 4: N-803 - IV 10 ug/kg
n=3 participants at risk
N-803: Intravenous infusion for cohort 1, 2, 3 and 4; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 5: N-803 - SQ 10 ug/kg
n=4 participants at risk
N-803: subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 6: N-803 - SQ 15 ug/kg
n=3 participants at risk
N-803: subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
Cohort 7: N-803 - SQ 20 ug/kg
N-803: subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
|
|---|---|---|---|---|---|---|---|
|
Gastrointestinal disorders
Dry mouth
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Psychiatric disorders
Insomnia
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Blood and lymphatic system disorders
Anaemia
|
66.7%
2/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
66.7%
2/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
50.0%
2/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Cardiac disorders
Cardiac arrest
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
25.0%
1/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Cardiac disorders
Sinus bradycardia
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Cardiac disorders
Sinus tachycardia
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
25.0%
1/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
50.0%
2/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Gastrointestinal disorders
Constipation
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
66.7%
2/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
25.0%
1/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Gastrointestinal disorders
Dental caries
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Gastrointestinal disorders
Diarrhoea
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
25.0%
1/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Gastrointestinal disorders
Dysphagia
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Gastrointestinal disorders
Gastrooesophageal reflux disease
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Gastrointestinal disorders
Nausea
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
75.0%
3/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Gastrointestinal disorders
Stomatitis
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
25.0%
1/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
General disorders
Administration site extravasation
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
General disorders
Chills
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
100.0%
3/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
66.7%
2/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
25.0%
1/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
66.7%
2/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
General disorders
Fatigue
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
66.7%
2/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
66.7%
2/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
25.0%
1/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
General disorders
Influenza like illness
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
General disorders
Injection site reaction
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
100.0%
4/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
General disorders
Mass
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
25.0%
1/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
General disorders
Oedema
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
25.0%
1/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
General disorders
Pain
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
50.0%
2/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
General disorders
Pyrexia
|
66.7%
2/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
100.0%
3/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
66.7%
2/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
75.0%
3/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
100.0%
3/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Immune system disorders
Hypersensitivity
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
66.7%
2/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Infections and infestations
Gingivitis
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Infections and infestations
Herpes simplex
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Infections and infestations
Lung infection
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Infections and infestations
Parainfluenzae virus infection
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Infections and infestations
Pneumonia
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Infections and infestations
Rhinitis
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
25.0%
1/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Infections and infestations
Upper respiratory tract infection
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
66.7%
2/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
25.0%
1/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Injury, poisoning and procedural complications
Fall
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Injury, poisoning and procedural complications
Infusion related reaction
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Injury, poisoning and procedural complications
Tooth fracture
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Investigations
Alanine aminotransferase increased
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
25.0%
1/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Investigations
Aspartate aminotransferase increased
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
25.0%
1/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Investigations
Blood alkaline phosphatase increased
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
25.0%
1/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Investigations
Blood bilirubin increased
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Investigations
Blood creatinine increased
|
66.7%
2/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
25.0%
1/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Investigations
Haptoglobin increased
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
25.0%
1/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Investigations
International normalised ratio increased
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
50.0%
2/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Infections and infestations
Lymphocyte count decreased
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
66.7%
2/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
75.0%
3/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Investigations
Neutrophil count decreased
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
66.7%
2/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
50.0%
2/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
66.7%
2/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Investigations
Platelet count decreased
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
66.7%
2/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
25.0%
1/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Investigations
Weight decreased
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
25.0%
1/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Investigations
White blood cell count decreased
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
50.0%
2/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
66.7%
2/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Metabolism and nutrition disorders
Decreased appetite
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
25.0%
1/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Metabolism and nutrition disorders
Dehydration
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Metabolism and nutrition disorders
Hypercalcaemia
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
25.0%
1/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
25.0%
1/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Metabolism and nutrition disorders
Hyperkalaemia
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
25.0%
1/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Metabolism and nutrition disorders
Hyperproteinaemia
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
25.0%
1/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Metabolism and nutrition disorders
Hypoalbuminaemia
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
50.0%
2/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Metabolism and nutrition disorders
Hypocalcaemia
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
25.0%
1/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Metabolism and nutrition disorders
Hypokalaemia
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
25.0%
1/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
66.7%
2/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
25.0%
1/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
100.0%
4/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Musculoskeletal and connective tissue disorders
Bone pain
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
25.0%
1/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Musculoskeletal and connective tissue disorders
Muscular weakness
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
25.0%
1/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal chest pain
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
25.0%
1/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
25.0%
1/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Basal cell carcinoma
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extradural neoplasm
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lipoma
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
25.0%
1/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Plasmacytoma
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
25.0%
1/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Nervous system disorders
Aphasia
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Nervous system disorders
Ataxia
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Nervous system disorders
Headache
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
25.0%
1/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Nervous system disorders
Hypoaesthesia
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
25.0%
1/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Nervous system disorders
Parkinson's disease
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Nervous system disorders
Peripheral sensory neuropathy
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Nervous system disorders
Presyncope
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Psychiatric disorders
Anxiety
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Psychiatric disorders
Confusional state
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
25.0%
1/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Renal and urinary disorders
Chronic kidney disease
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Renal and urinary disorders
Pollakiuria
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Renal and urinary disorders
Proteinuria
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
25.0%
1/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Respiratory, thoracic and mediastinal disorders
Productive cough
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
25.0%
1/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Skin and subcutaneous tissue disorders
Dermatitis bullous
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Skin and subcutaneous tissue disorders
Hyperhidrosis
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Skin and subcutaneous tissue disorders
Rash maculo-papular
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Vascular disorders
Hypertension
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
33.3%
1/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
66.7%
2/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
|
Vascular disorders
Hypotension
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
66.7%
2/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/4 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
0.00%
0/3 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
—
0/0 • Treatment-related and non-treatment-related adverse events were monitored/assessed up to 33 weeks. Patients who have an on-going study drug-related SAE upon study completion/discontinuation will be contacted by PI/designee until event is resolved/determined to be irreversible, up to 33 weeks.
Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place